PROCEPT BIOROBOTICS CORPORATION EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement"), entered into effective as of July 23, 2025 (the "Execution Date"), is between Larry L. Wood ("Executive") and PROCEPT BioRobotics Corporation, a Delaware corporation ("PROCEPT" or the "Company"). Executive's first day of employment with the Company will be September 2, 2025 (the "Effective Date"). WHEREAS, the Company desires to assure itself of the services of Executive by engaging Executive to perform service ...

Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO ...

SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conferen ...

Core Insights - PROCEPT BioRobotics Corporation announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, marking a significant milestone for the company and the urology community [1][3] - The new Category I CPT code 52XX1 will replace the previous Category III CPT code 0421T and is associated with a proposed national average payment of approximately $540 under the 2026 Medicare Physician Fee Schedule [2][3] - The transition to a Category I code is expected to enhance surgeon adoption and increase patient access to Aquablation therapy, which offers durable symptom relief with a low risk of sexual side effects [3] Payment Structure - The 2026 proposed payment for Aquablation therapy is set at 16.14 total RVUs, compared to 15.82 total RVUs for TURP, which translates to an average payment of approximately $529 [3] - The Proposed Physician Fee Schedule was released on July 14, 2025, and will undergo a public comment period until September 2025, with a final rule expected in November 2025 [4] Aquablation Therapy Overview - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for benign prostatic hyperplasia (BPH), providing personalized treatment planning based on real-time imaging [5][6] - The technology allows for precise removal of prostate tissue while preserving critical anatomy related to erectile and ejaculatory function, making it suitable for a wide range of patients [5][6] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for Aquablation therapy [6]

BPH Market & Aquablation Therapy - Benign Prostatic Hyperplasia (BPH) affects approximately 40 million men in the U S [21] - The U S BPH surgical market represents a ~$20 billion opportunity [27] - Approximately 70% of prostates treated with Aquablation in the U S are less than 100ml in size [41] - Aquablation therapy provides effective, safe, and durable outcomes independent of prostate size, shape, and surgeon experience [36] Financial Performance & Guidance - Total revenue increased by 72% year-over-year to $24 4 million in Q1 2023 [51] - U S Aquabeam install base increased by 106% year-over-year to 192 systems in Q1 2023 [51] - U S handpieces sold increased by 139% year-over-year in Q1 2023 [51] - The company projects total revenue of $128 0 million for 2023, representing approximately 71% year-over-year growth [53, 54] - The company anticipates a gross margin of 54% for 2023 [54] Commercial Strategy & Expansion - The company is targeting 860 high-volume hospitals in the U S with an annual resective volume of ≥100 procedures [62] - 17 Strategic IDNs account for ~29% of BPH hospitals and ~26% of high-volume centers [70] - 65% of high volume hospitals are within a 100-mile radius of Robotic Sales Representatives [73]

Investor Event © 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forw ard-looking statements" w ithin the meaning of the Private Securities Litigation Reform Act of 1995, including the ex pected financial results of PROCEPT BioRobotics Corporation (the "Company"). W ords such as "anticipates," "believes," "ex pects," "intends," "projects," "anticipates," and "f uture" or similar ex pressions are intended to identi ...

Investor Event 2025 American Urological Association Annual Meeting April 25, 2025 © PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipates," "believes," "expects," "intends," "projects," "anticipates," and ...

Summary of PROCEPT BioRobotics (PRCT) 2025 Conference Call Company Overview - **Company**: PROCEPT BioRobotics (PRCT) - **Industry**: Medical Technology, specifically focusing on surgical solutions for Benign Prostatic Hyperplasia (BPH) Key Points and Arguments Business Trends and Performance - **Q1 Performance**: The company experienced a strong procedure beat in Q1, with positive momentum continuing into April and May, indicating a rebound from previous challenges such as saline shortages [2][3][4] - **Surgeon Metrics**: Surgeon retention rates remain above 90%, and the company is seeing growth in new account launches and multiple surgeon engagements [4][3] - **Utilization Growth**: The company anticipates low to mid-single-digit year-over-year growth in utilization, which is viewed positively given the number of systems being added annually [8][11] Capital Component and Product Launch - **Hydro System Launch**: The Hydro system is early in its launch phase but has shown great receptivity, with a significant sales funnel and positive selling prices [4][5] - **Market Penetration**: The AquaBlation program currently holds about 50% market share within existing accounts, with expectations for further market expansion [11][19] - **Future Installations**: The company plans to install over 200 robots in 2025, which will contribute to incremental procedures despite a ramp-up period of three to four quarters for new accounts [12][11] IDN Relationships and Sales Strategy - **IDN Engagement**: The company has increased its engagement with Integrated Delivery Networks (IDNs), which account for 25% to 30% of all BPH surgeries in the U.S. This is seen as crucial for becoming the standard of care in the surgical BPH space [33][34] - **Predictability in Sales**: Relationships with IDNs are expected to improve the predictability of capital sales, allowing for better resource allocation [37][39] Pricing and Market Environment - **Average Selling Price (ASP)**: The average selling price of the robots has increased from approximately $300,000 at the time of going public to around $430,000 to $440,000, indicating strong demand and value perception [41][42] - **Capital Environment**: The company does not sense a material shift in overall sentiment regarding the capital environment, maintaining that their products are viewed as beneficial for hospitals, which helps in retaining patients and surgeons [45][47] Reimbursement and Regulatory Considerations - **CPT Code Change**: The transition from Category III to Category I CPT codes is expected to have a minimal impact on physician fees, with a slight decrease anticipated but not affecting adoption rates [49][50] - **Facility Payment**: The company expects to maintain its APC level six status, which is crucial for facility reimbursement, and has seen an increase in procedure pricing over the past 12 to 24 months [51][52] Future Outlook and Prostate Cancer Treatment - **Prostate Cancer Treatment**: The company is addressing concerns about the potential spread of cancer during procedures and has received FDA support for treating patients with known prostate cancer. They aim to enroll the majority of patients within 18 months, with commercialization expected by early 2028 [66][69][72] Additional Important Insights - **Operational Efficiency**: The Hydro system is designed to improve operational efficiency in hospitals, reducing reliance on specific staff and potentially increasing profitability for hospitals [22][23] - **Market Expansion**: The company is focused on penetrating high-volume hospitals while also seeing interest from medium-volume hospitals, which are expected to follow similar utilization trajectories as high-volume hospitals [28][30] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics conference call, highlighting the company's growth potential, market strategies, and future plans in the medical technology sector.

PROCEPT BioRobotics (PRCT) FY Conference June 04, 2025 11:00 AM ET Speaker0 Hello? Sorry. Hi, everyone. My name is Brandon Vasquez. I am the analyst here at William Blair that covers Procept biorobotics. I am required to tell you and inform you to go to our website at williamblair.com a complete list of disclosures and conflicts of interests. With that said, happy to have president and CEO Reza Zadno with us. He's gonna run us through a company presentation before we go to our breakout. So with that, I'll t ...

Summary of PROCEPT BioRobotics (PRCT) Q1 2025 Conference Call Company Overview - **Company**: PROCEPT BioRobotics (PRCT) - **Industry**: Medical Technology Key Points Q1 Performance and Guidance - Q1 procedures exceeded expectations with 11,200 cases completed, surpassing the guidance of 10,700, representing a year-over-year increase of approximately 4.5% [4][5] - The company maintained its full-year guidance despite the strong Q1 performance, reflecting a conservative approach due to market conditions [5][12] - Monthly procedure growth showed improvement: February was better than January, and March was better than February [3] Capital Expenditure (CapEx) and Systems Sales - Q1 systems sales met expectations, with the average selling price at the high end of guidance [11] - The company noted that Q1 is typically challenging for capital equipment sales due to unvetted hospital budgets, but they are optimistic about the sales funnel for the remainder of the year [10] Utilization and Procedures - Utilization in Q1 was reported at 7.1%, with a 5% growth [15] - The company did not provide specific quarterly guidance for procedures but expressed confidence in meeting market expectations for Q2 and Q3 [18] - The company tracks metrics such as active surgeons and utilization rates, indicating positive trends in surgeon engagement and case volume [20][22] Tariffs and Gross Margin Impact - The company faced a tariff impact of approximately $5 million on gross margins due to a 145% import tariff on key components from China, which has since been reduced to 30% [30][31] - The anticipated impact on gross margins is now estimated to be between $1 million to $2 million, significantly less than previously communicated [31] Reimbursement and CPT Code Change - The transition from a Category 3 to a Category 1 CPT code is expected to occur in summer 2025, with no significant changes anticipated in reimbursement rates compared to other resective procedures [33][40] - The company expects to remain competitive in reimbursement rates, aligning with existing procedures in the market [39] Prostate Cancer Opportunity - The company is exploring opportunities in prostate cancer treatment, with a focus on minimizing side effects such as incontinence and erectile dysfunction [42] - Initial studies have shown promising results, and the company is optimistic about the potential market size, estimating significant revenue growth from prostate cancer procedures by 2028 [49][51] Financial Outlook - The company is on track to potentially achieve EBITDA breakeven by Q4 2025, although this is not the primary focus as they prioritize growth investments [55][57] - Gross margin expansion is expected to continue, driven by leveraging fixed costs as the business scales [58][59] Additional Insights - The management emphasizes a long-term growth strategy, focusing on maintaining a balance between investment in growth and achieving profitability [57] - The company has a robust cash position of $300 million, providing a strong foundation for future growth initiatives [57] This summary encapsulates the key insights and data points from the PROCEPT BioRobotics Q1 2025 conference call, highlighting the company's performance, strategic outlook, and market opportunities.